Home > Oncology > No survival boost from ipilimumab-pembrolizumab combo in NSCLC

No survival boost from ipilimumab-pembrolizumab combo in NSCLC

Journal of Clinical Oncology
Reuters Health - 04/02/2021 - Adding ipilimumab to pembrolizumab did not improve survival and was more toxic, compared with pembrolizumab alone, as a first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC) in the KEYNOTE-598 trial. "Pembrolizumab monotherapy remains a standard of care first-line treatment for this group of patients," said lead researcher Dr. Michael Boyer of the University of Sydney, Australia, in reporting the results at the International Association for the Study of Lung Cancer (IASLC) virtual World Conference on Lung Cancer. The results were published simultaneously in the Journal of Clinical Oncology. The KEYNOTE-598 phase-3 trial enrolled 568 patients with stage-IV NSCLC, a PD-L1 tumor proportion score of 50% or greater and no EGFR or ALK aberrations. Half were randomly allocated to ipilimumab at 1 mg/kg every six weeks and half to saline placebo for up to 18 cycles. Patients in both groups received 200 mg of...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on